Sanofi Partnership On Oral IL-17 Could Be Turning Point For C4XD
May Validate Small Molecule Platform
The UK drug discovery specialist has made slow progress until now, but the Sanofi deal could yield a challenger in the competitive psoriasis field.
You may also be interested in...
The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.
Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.
Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.